
|Videos|June 30, 2022
Dr. Tian Zhang discusses tivozanib for advanced kidney cancer
Author(s)Urology Times staff
Advertisement
Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses the FDA-approved therapy tivozanib (Fotivda) for patients with relapsed or refractory advanced renal cell carcinoma, including ongoing trials further exploring the agent.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












